Not provided
Not provided
Not provided
Not provided
Not provided
No participants were enrolled
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a study looking at the use of sodium bicarbonate to restore the flow of blocked central line devices in patients with blood cancers.
Central line devices uses thin tubes that are placed into a vein in the body to give medicines, fluids, nutrients, blood products, etc.
Sometimes, the lines become blocked. The standard procedure to get the line working again is to use alteplase, a protein that dissolves blood clots. While blood clotting is one cause of a blocked line, other reasons included the formation of calcium deposits. Sodium bicarbonate is routinely used in the treatment of patients receiving chemotherapy. Sodium bicarbonate is a liquid drug which is capable of dissolving protein and calcium deposits.
This study will compare whether sodium bicarbonate works just as well as alteplase to recover the function of a blocked line.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Alteplase then Sodium Bicarbonate | Experimental | Alteplase will first be administered to restore flow. If flow is not restored, then sodium bicarbonate will be administered. |
|
| Sodium Bicarbonate then Alteplase | Experimental | Sodium bicarbonate will first be administered to restore flow. If flow is not restored, then alteplase will be administered. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sodium Bicarbonate 8.4% Solution for Injection | Drug | 3 mL injection into line with up to 2 injections administered |
|
| Measure | Description | Time Frame |
|---|---|---|
| Successful clearance rate of sodium bicarbonate | 3 hours | |
| Successful clearance rate of alteplase | 3 hours |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mark Minden, M.D. | Princess Margaret Cancer Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Princess Margaret Cancer Centre | Toronto | Ontario | M5G 2M9 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017693 | Sodium Bicarbonate |
| D012996 | Solutions |
| D007267 | Injections |
| ID | Term |
|---|---|
| D001639 | Bicarbonates |
| D002254 | Carbonates |
| D002255 | Carbonic Acid |
| D017554 | Carbon Compounds, Inorganic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Alteplase Injectable Solution | Drug | 2 mL injection into line with up to 2 injections administered |
|
| D007287 |
| Inorganic Chemicals |
| D017670 | Sodium Compounds |
| D004364 | Pharmaceutical Preparations |
| D004333 | Drug Administration Routes |
| D004358 | Drug Therapy |
| D013812 | Therapeutics |